Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, 330 Cedar Street, New Haven, CT, 06510, USA.
University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT, 06032, USA.
J Immunother Cancer. 2017 Oct 17;5(1):78. doi: 10.1186/s40425-017-0284-8.
The use of immunomodulation to treat malignancies has seen a recent explosion in interest. The therapeutic appeal of these treatments is far reaching, and many new applications continue to evolve. In particular, immune modulating drugs have the potential to enhance the systemic anticancer immune effects induced by locoregional thermal ablation. The immune responses induced by ablation monotherapy are well documented, but independently they tend to be incapable of evoking a robust antitumor response. By adding immunomodulators to traditional ablative techniques, several researchers have sought to amplify the induced immune response and trigger systemic antitumor activity. This paper summarizes the work done in animal models to investigate the immune effects induced by the combination of ablative therapy and immunomodulation. Combination therapy with radiofrequency ablation, cryoablation, and microwave ablation are all reviewed, and special attention has been paid to the addition of checkpoint blockades.
免疫调节治疗恶性肿瘤的研究近期兴趣大增。这些治疗方法具有深远的治疗意义，并且不断有新的应用出现。特别是免疫调节药物具有增强局部热消融诱导的全身性抗癌免疫效应的潜力。消融单药治疗诱导的免疫反应已有充分的文献记载，但独立应用时往往无法引发强烈的抗肿瘤反应。通过将免疫调节剂加入传统的消融技术中，一些研究人员试图放大诱导的免疫反应并引发全身性抗肿瘤活性。本文总结了在动物模型中进行的研究工作，以探讨消融治疗与免疫调节联合治疗所诱导的免疫效应。本文综述了射频消融、冷冻消融和微波消融联合治疗的研究，并特别关注了检查点阻断的加入。
